Frédéric has over 20 years of experience in early stage development. He co-founded LASCCO (2007), Combioxin (2015) and PalmeaPharma (2023). Frédéric has specialized in translation from discovery-stage to clinical stage biomedical technologies in the fields of immunology, infectious diseases and sepsis. Prior to that, Frédéric was product manager at Abbott Laboratories for the HIV/Virology pharmaceuticals Swiss market where he set up various Phase 4 clinical studies with Kaletra, Abbott’s anti-HIV blockbuster, and oversaw global marketing programs at the European level. Frédéric holds a PhD in biology, with a specialization in immunology, from the University of Paris VII. He carried out a post-doctoral work at the Geneva University Hospital studying autoimmune disorders. Frédéric also holds an MBA with a specialization in Entrepreneurship from the University of Geneva.

Samareh is an early-stage drug development specialist. She co-founded, in 2007, LASCCO, a Swiss start-up company focusing on the development of discovery-stage biomedical technologies. Since then, she managed the development of new pharmaceuticals in the field of infectious diseases and inflammatory disorders (Sepstone Diagnostics Sàrl, Combioxin SA, PalmeaPharma SA). With Combioxin, Samareh has headed the clinical and operational team for the development of CAL02, a first-in-class anti-toxin drug for the treatment of severe bacterial pneumonia. She has been involved in PalmeaPharma since inception. She is regularly invited to write reviews in peer-reviewed journals and to give oral presentations in universities and congresses. Samareh holds a PhD. from the Swiss Polytechnical School of Lausanne EPFL, where she was the first recipient of the EPFL fellowship award in life sciences. She was rewarded as one of the 100 outstanding personalities contributing to the dynamism and innovation spirit in Switzerland.

Toni holds more than 37 years of experience in the development of pharmaceuticals. He is a specialist in intensive care medicine and infectious diseases, with diplomas of Pharmaceutical Industry and General Management Program. Toni has held several positions, among which local Head of Development of Anti-Infectives at Novartis and at F. Hoffmann-La Roche´s spin-off Basilea Pharmaceutica, Head of Development at Almirall, Medical Director and member of the Board of Directors at Esteve. Toni has contributed to the development, registration, launch and marketing of several medicines in infectious diseases as well as in oncology and neurology.